[의학신문·일간보사=김영주 기자]SK Chemicals (CEO Jeon Kwang-hyun) announced on the 15th that it has signed a’domestic sales agreement’ for the family of’Ultraset’ (acetaminophen, trimadol hydrochloride) to strengthen its analgesic anti-inflammatory portfolio with Janssen Korea (CEO Jenny Jung).
 |
| 4 Ultraset family items that SK Chemicals is in charge of |
Under this agreement, SK Chemicals is responsible for distribution and domestic marketing and sales of Ultraset. Janssen Korea will be in charge of production. There are 4 types of contracted products: Ultraset Tablet, Ultraset Semi Tablet, Ultraset RSemi Tablet, and Ultraset RSemi Tablet.
The sales agreement between SK Chemicals and Janssen Korea is the second in 2019 after Reminil, a dementia treatment drug.
This ultraset, introduced by SK Chemicals, was first developed in 2002 and is one of the most widely used pain relievers around the world. Ultraset has a broad pain spectrum, from moderate to severe pain. There is no need to worry about side effects such as addiction or drug abuse because there is no drug component that was included in many effective pain relievers.
“Through this agreement, our portfolio of analgesic anti-inflammatory drugs has been further strengthened,” said Kim Jeong-hoon, head of SK Chemicals Pharma Planning Office. “We will contribute to improving the quality of life for domestic consumers through synergy with existing anti-pain products.”
Reporter Kim Young-joo [email protected]
<저작권자 © 의학신문, 무단 전재 및 재배포 금지>